PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
Taking everything into account, PBH scores 6 out of 10 in our fundamental rating. PBH was compared to 198 industry peers in the Pharmaceuticals industry. PBH gets an excellent profitability rating and is at the same time showing great financial health properties. PBH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
In the past year PBH had a positive cash flow from operations.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PBH (6.31%) is better than 90.40% of its industry peers.
PBH has a better Return On Equity (11.70%) than 87.88% of its industry peers.
The Return On Invested Capital of PBH (8.02%) is better than 85.35% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBH is significantly below the industry average of 42.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROIC | 8.02% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH's Profit Margin of 18.86% is amongst the best of the industry. PBH outperforms 91.92% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
With an excellent Operating Margin value of 30.70%, PBH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
PBH's Operating Margin has been stable in the last couple of years.
The Gross Margin of PBH (55.76%) is better than 65.15% of its industry peers.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.05 indicates that PBH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.05, PBH is in the better half of the industry, outperforming 76.26% of the companies in the same industry.
The Debt to FCF ratio of PBH is 4.17, which is a neutral value as it means it would take PBH, 4.17 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.17, PBH belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 61.62% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Altman-Z | 3.05 |
ROIC/WACC0.85
WACC9.43%
2.3 Liquidity
A Current Ratio of 4.20 indicates that PBH has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.20, PBH is doing good in the industry, outperforming 67.17% of the companies in the same industry.
A Quick Ratio of 2.82 indicates that PBH has no problem at all paying its short term obligations.
With a Quick ratio value of 2.82, PBH perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.63%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
PBH shows a small growth in Revenue. In the last year, the Revenue has grown by 1.10%.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
3.2 Future
The Earnings Per Share is expected to grow by 4.69% on average over the next years.
The Revenue is expected to grow by 2.10% on average over the next years.
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.69%
Revenue Next Year1.58%
Revenue Next 2Y1.87%
Revenue Next 3Y1.92%
Revenue Next 5Y2.1%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.93, the valuation of PBH can be described as rather expensive.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 83.84% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Earnings ratio to 25.82, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 17.80, PBH is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PBH is valued a bit cheaper than 77.27% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PBH to the average of the S&P500 Index (21.76), we can say PBH is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.93 | ||
| Fwd PE | 17.8 |
4.2 Price Multiples
PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 80.81% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 85.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.46 | ||
| EV/EBITDA | 13.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)2.98
PEG (5Y)2.13
EPS Next 2Y5.88%
EPS Next 3Y5.22%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
85.75
+0.74 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.91%
Inst Owner Change-1.24%
Ins Owners1.33%
Ins Owner Change6.47%
Market Cap4.25B
Analysts78
Price Target90.78 (5.87%)
Short Float %3.24%
Short Ratio4.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.47%
Min EPS beat(2)0.64%
Max EPS beat(2)4.3%
EPS beat(4)3
Avg EPS beat(4)2.01%
Min EPS beat(4)-0.47%
Max EPS beat(4)4.3%
EPS beat(8)5
Avg EPS beat(8)-0.35%
EPS beat(12)8
Avg EPS beat(12)-46.35%
EPS beat(16)12
Avg EPS beat(16)-31.94%
Revenue beat(2)2
Avg Revenue beat(2)0.9%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.46%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)1.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.39%
Revenue beat(12)6
Avg Revenue beat(12)0.09%
Revenue beat(16)10
Avg Revenue beat(16)1.7%
PT rev (1m)-2.73%
PT rev (3m)1.33%
EPS NQ rev (1m)-5.02%
EPS NQ rev (3m)-4.26%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)-5.36%
Revenue NQ rev (3m)-5.19%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)-0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.93 | ||
| Fwd PE | 17.8 | ||
| P/S | 3.73 | ||
| P/FCF | 17.46 | ||
| P/OCF | 16.89 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.52 |
EPS(TTM)4.53
EY5.28%
EPS(NY)4.82
Fwd EY5.62%
FCF(TTM)4.91
FCFY5.73%
OCF(TTM)5.08
OCFY5.92%
SpS22.97
BVpS37.04
TBVpS-19.94
PEG (NY)2.98
PEG (5Y)2.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROCE | 10.6% | ||
| ROIC | 8.02% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 70.49% | ||
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% | ||
| FCFM | 21.38% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 27.26% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.31 | ||
| Cash Conversion | 66.29% | ||
| Profit Quality | 113.37% | ||
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 | ||
| Altman-Z | 3.05 |
F-Score7
WACC9.43%
ROIC/WACC0.85
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.69%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
Revenue Next Year1.58%
Revenue Next 2Y1.87%
Revenue Next 3Y1.92%
Revenue Next 5Y2.1%
EBIT growth 1Y1.99%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.41%
EBIT Next 3Y5.43%
EBIT Next 5Y4.21%
FCF growth 1Y1.64%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y1.04%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%